Equitable access to new modalities: from innovation to reimbursement

Innovators developing therapeutics and diagnostics with non-traditional modalities should think about paths to equitable access from the earliest stages of R&D, while policies from regulators, funders and tech transfer offices should aim to bolster those paths in the face of financial pressures.

These were among the takeaways of a panel hosted by the trade group California Life Sciences on Aug. 15, which included innovators who spun out gene therapies from University of California San Diego and next-generation diagnostics from Stanford University, and policy leaders from CLS and the gene editing-focused Innovative Genomics Institute (IGI)...